
A high-profile informant emerged earlier this month in a federal lawsuit against an illegal prescription drug business and two of its top executives. That’s the CEO of another company in the same industry that authorities allege had committed similar import violations.
John Thomas Howard, the financial director and director of a Canadian healthcare company called CANARX, was arrested on Nov. 8 in a tunnel connecting Detroit and Canada and charged with smuggling, conspiracy, and importing counterfeit branded drugs for patient use in the United States. His brother, Bob Howard, the company’s president, is also wanted on similar charges and was still being sought as of last week, according to court records.
The charges are the first criminal charges brought by U.S. authorities against companies that are part of a cottage industry known as Alternative Financing Programs (AFP), which promises to lower or eliminate high prescription drug costs for Americans.
Cheap medicines are typically sourced from international markets, but the Food and Drug Administration and the Department of Homeland Security argue that this business model is illegal and can put patients’ health at risk.
At issue is the lack of regulation of medicines destined for overseas markets and, in some cases, the risk of counterfeiting. AFP also generally maintains that the importation of medicines by individuals for personal use is allowed under U.S. law, but authorities say the practice goes too far.
Windsor, Ontario-based CANARX was founded in 2002 and was featured in a CNBC investigation into the booming AFP industry.
Joseph Morris, general counsel for CANARX, told CNBC last year that the company operates legally and is confident in the safety of the prescriptions it provides. Morris told CNBC last week that the Howard brothers “deny all charges, intend to vigorously defend themselves, and look forward to being exonerated in court.”
CEO turned informant
The FDA’s case against CANARX began with a tip about a similar medical practice called ScriptSourcing. The case is detailed in a 35-page affidavit, dated Oct. 29 and unsealed last week, written by Dustin Dobbs, a special agent in charge of the FDA’s Office of Criminal Investigation.
Bonita Springs, Fla.-based ScriptSourcing sold an international prescription program for self-funded employer health plans. Founder and CEO Gary Becker is described on the company’s website as a “health insurance and risk management consultant for over 30 years.”
ScriptSourcing has been on the FDA’s radar for potential drug import violations since at least 2022, according to the affidavit. In August 2025, Mr. Dobbs sent an email to ScriptSourcing, posing as someone interested in AFP business, asking if the company was FDA compliant.
In response to Dobbs, Script Sourcing employees said the company is FDA compliant, has more than 2,000 name-brand specialty drugs, and works with more than 3,000 self-funded health plans.
But that same year, authorities learned of two incidents in which drugs from Script Sourcing’s international drug import program were suspected of harming patients, according to Dobbs’ affidavit. One patient was hospitalized with a small bowel obstruction after using a counterfeit brand of Mounjaro, which the company supplied through a Canadian pharmacy, and the other was allegedly seriously injured after receiving the counterfeit drug.
In the face of intense FDA scrutiny, ScriptSourcing CEO Becker slammed CANARX’s Howard brothers.
By May 2026, Dobbs wrote, Becker was a cooperating witness in the government’s investigation into the Canadian company. According to the affidavit, Becker told the FDA that he had done business with CANARX for drug imports and that the company had given him a “road map” on how to proceed with the business.
Script Sourcing provided FDA with a spreadsheet of financial transactions with CANARX from 2021 to 2026. That shows approximately 16,549 prescriptions were filled, the affidavit states.
Later, in several recorded phone calls between June and July 2026, Mr. Becker discussed foreign imports with the Howard brothers.
The call “indicates that John Howard was aware of the drug import route from Canada to the United States and was attempting to shape the route to fit into (CANARX’s) illegal drug import program,” Dobbs wrote in the affidavit. “These calls demonstrate that John Howard and Bob Howard were aware that these drugs were not legally allowed to be brought into the United States.”
At the time the information was provided, CANARX was shipping or preparing packages containing Nupro, which is regulated by the FDA as a treatment for Parkinson’s disease and restless leg syndrome.
The FDA did not respond to a request for comment from CNBC regarding the details of the affidavit.
Gary Becker’s lawyer, George Karavetzos, declined to comment to CNBC, but confirmed on Monday that Script Sourcing is no longer in business.
AFP’s position
AFP’s business model was initially at the center of a civil lawsuit filed by AFP. Gilead Sciences In December 2024, several companies, including CANARX, were accused of illegally importing the company’s HIV treatment Biktarvy. CANARX has not responded to Gilead’s allegations.
Gilead said in a statement to CNBC last week following the accusations against the Howard brothers that it “welcomes the government’s efforts to hold accountable those whose actions may put patients at risk.”
“Drugs manufactured for foreign markets are almost always considered unapproved and misbranded drugs under U.S. law, even if they are counterfeit or made by the same manufacturer that produces those sold in the United States,” Dobbs said in an affidavit.
—CNBC’s Melissa Lee and Paige Tortorelli contributed to this report.
